The 19th Annual BIO CEO & Investor Conference
Company presentation by Josh Hexter, Chief Operating Officer Date: Monday, February 13, 2017 Time: 11:00 a.m. EST Location: The Waldorf Astoria, New York City, Duke of Windsor Room
Oramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences
JERUSALEM, Feb. 7, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Investor Conference, taking place February 13-14, 2017 [...]
2016 Aegis Growth Conference
Company presentation by David Slager, Director of Oramed Date: Wednesday, September 21, 2016 Time: 2:00pm PST Location: The Encore at Wynn, 3. Life Science Room
BioTuesdays: Oramed hopes to start Phase 3 oral insulin trial next year
Josh Hexter, Oramed’s COO, spoke with BioTuesdays.com about the conclusion of the Phase IIb study, and about what's next for Oramed: Oramed hopes to start Phase 3 oral insulin trial next year
SEEKING ALPHA: Oramed Is Now The First To Show Evidence That Insulin Can Be Taken Orally
Injectable insulin has been around since 1923, but oral insulin has proven elusive to date. Oramed Pharmaceuticals' successful Phase IIB trial for oral insulin has shown that it can be done. http://seekingalpha.com/article/3987206-oramed-now-first-show-evidence-insulin-can-taken-orally
I24 News : Israeli Drugmaker Oramed Successfully Tests Insulin Pill
http://www.i24news.tv/en/tv/replay/evening-news/x4jqi3z
Biopharma Dive: Oramed’s oral insulin shines in mid-stage trials
Creating a safe, effective, tolerable oral insulin has become the holy grail of diabetes drug development, and Israel-based Oramed is one of the frontrunners in this race... http://www.biopharmadive.com/news/orameds-oral-insulin-shines-in-mid-stage-trials/419657/
Market Exclusive: Weekly Biotech Report Part II, Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP)
https://marketexclusive.com/weekly-biotech-report-part-ii-oramed-pharmaceuticals-inc-nasdaqormp/2016/05/
Reuters: Oramed Says Oral Insulin Succeeds in Midstage Type 2 Diabetes Trial
http://www.reuters.com/article/us-oramed-insulin-idUSKCN0Y91F2
Be Forum: Dancing With Dragons, How a Small Israeli Company Struck a Historic Deal with a Chinese Giant
Josh Hexter, Oramed's COO, spoke with Be Forum and about the company's recent China deal. www.beforum.org/the-bulletin/dancing-with-dragons